1. Home
  2. SNDX vs FSUN Comparison

SNDX vs FSUN Comparison

Compare SNDX & FSUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • FSUN
  • Stock Information
  • Founded
  • SNDX 2005
  • FSUN 1892
  • Country
  • SNDX United States
  • FSUN United States
  • Employees
  • SNDX N/A
  • FSUN N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • FSUN Major Banks
  • Sector
  • SNDX Health Care
  • FSUN Finance
  • Exchange
  • SNDX Nasdaq
  • FSUN Nasdaq
  • Market Cap
  • SNDX 1.1B
  • FSUN 997.3M
  • IPO Year
  • SNDX 2016
  • FSUN N/A
  • Fundamental
  • Price
  • SNDX $9.00
  • FSUN $37.69
  • Analyst Decision
  • SNDX Strong Buy
  • FSUN Buy
  • Analyst Count
  • SNDX 10
  • FSUN 4
  • Target Price
  • SNDX $35.80
  • FSUN $47.33
  • AVG Volume (30 Days)
  • SNDX 1.8M
  • FSUN 193.0K
  • Earning Date
  • SNDX 07-31-2025
  • FSUN 08-27-2025
  • Dividend Yield
  • SNDX N/A
  • FSUN N/A
  • EPS Growth
  • SNDX N/A
  • FSUN N/A
  • EPS
  • SNDX N/A
  • FSUN 3.07
  • Revenue
  • SNDX $43,722,000.00
  • FSUN $374,445,000.00
  • Revenue This Year
  • SNDX $426.77
  • FSUN $18.18
  • Revenue Next Year
  • SNDX $98.31
  • FSUN $6.75
  • P/E Ratio
  • SNDX N/A
  • FSUN $12.29
  • Revenue Growth
  • SNDX N/A
  • FSUN 9.58
  • 52 Week Low
  • SNDX $8.58
  • FSUN $31.70
  • 52 Week High
  • SNDX $25.07
  • FSUN $45.32
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 38.70
  • FSUN 69.79
  • Support Level
  • SNDX $8.77
  • FSUN $33.44
  • Resistance Level
  • SNDX $9.50
  • FSUN $35.01
  • Average True Range (ATR)
  • SNDX 0.53
  • FSUN 1.15
  • MACD
  • SNDX -0.04
  • FSUN 0.47
  • Stochastic Oscillator
  • SNDX 14.13
  • FSUN 87.87

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About FSUN FirstSun Capital Bancorp

Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments - Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.

Share on Social Networks: